What Happened?
Waltham, MA-based Histogenics Promoted Stephen Kennedy as Chief Technology Officer
About the Company
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
About the Person
Stephen Kennedy is Senior Vice President and Head of Technical Operations at Casebia. Previously, Stephen held various senior IT leadership roles in the industry.
Info Source
News
Short Profile